GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » Total Current Liabilities

Jenscare Scientific Co (HKSE:09877) Total Current Liabilities : HK$68.55 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Jenscare Scientific Co's total current liabilities for the quarter that ended in Dec. 2024 was HK$68.55


Jenscare Scientific Co Total Current Liabilities Historical Data

The historical data trend for Jenscare Scientific Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co Total Current Liabilities Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
21.76 60.86 63.36 64.18 68.55

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only 63.36 56.84 64.18 55.69 68.55

Jenscare Scientific Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Jenscare Scientific Co's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=35.136+19.227
+Other Current Liabilities+Current Deferred Liabilities
=14.183+0
=68.55

Jenscare Scientific Co's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=35.136+19.227
+Other Current Liabilities+Current Deferred Liabilities
=14.183+0
=68.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Jenscare Scientific Co Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Jenscare Scientific Co Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Lv Shiwen 2501 Other
Li Hui 2501 Other
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Onez International Limited 2101 Beneficial owner
Pan Fei 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Trinity Elite I International Limited 2201 Interest of corporation controlled by you
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner

Jenscare Scientific Co Headlines

No Headlines